The Valley Desk

ArticleAdvances in therapyPublished

Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Advances in therapy
Published
Subject terms
Indirect Treatment Comparison; Inverse Probability Of Treatment Weighting; Relapsed Or Refractory Multiple Myeloma; Teclistamab And Daratumumab
PubMed ID
42970164
Added to directory
Source checked

Report a correction or request removal